%0 Journal Article
%T Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents.
%A Mastorino L
%A Richiardi I
%A Gelato F
%A Cavaliere G
%A Quaglino P
%A Ortoncelli M
%A Ribero S
%J Expert Opin Biol Ther
%V 0
%N 0
%D 2024 Jun 25
%M 38913354
%F 5.589
%R 10.1080/14712598.2024.2372367
%X <B>UNASSIGNED: </B>There are currently limited data on dupilumab drug survival (DS), especially on factors possibly associated with drug discontinuation.<BR><B>UNASSIGNED: </B>The primary endpoint of this study is to evaluate the parameters that may determine drug discontinuation and the predictive factors associated with dupilumab DS. We considered as independent associated factors: childhood onset of disease, gender, age of onset of AD, age of initiation of dupilumab, previous use of cyclosporine, initial mean EASI, atopic family history, and predisposition to allergic conjunctivitis.<BR><B>UNASSIGNED: </B>On 413 patients DS was 94.5% at 1 year, 89.5% at 2 years, and 83.7% at 3 years, and after a mean follow-up of 40.5 months (±1.6) 53 patients had discontinued the drug permanently (12.8%). Univariate analysis showed that the only factor associated with a reduction in drug survival was a predisposition to allergic conjunctivitis (p 0.009). At multivariate Cox regression, male sex (HR, 2.34; 95% CI, 1.14-4.78; p 0.02) and predisposition to allergic conjunctivitis (HR, 2.61; 95% CI, 1.37-5.00; p 0.004) were associated with lower DS of dupilumab.<BR><B>UNASSIGNED: </B>Male gender and predisposition to allergic conjunctivitis are negative predictors for maintenance of response to treatment with dupilumab and consequently associated with lower DS rates.